HALO
Halozyme Therapeutics
$81.48
−$0.45 (−0.55%)Jul 27, 2026
Key metrics
The numbers that frame HALO today
- Market cap
- $9.66B
- P/E (TTM)
- 27.7
- EV / FCF
- 17.2
- Gross margin
- 82.8%
- EV / Sales
- 7.6
- ROIC
- 21.6%
- Div yield
- 0%
- Debt / equity
- 9.8
- 52wk Low
- $57.68
- 52wk High
- $83.50
Growth
Revenue and earnings trend for HALO
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about HALO
Is Halozyme Therapeutics a good buy?
Yes. Halozyme Therapeutics has excellent quality and strong momentum. Both signals support the setup. Growth looks excellent, which supports the long-term business case. We think Halozyme Therapeutics is selling at a low price.
What is the market capitalization of HALO?
Halozyme Therapeutics's market capitalization is $9.66B.
What is the P/E ratio for HALO stock?
Halozyme Therapeutics's current P/E ratio is 27.7.
What is the 52-week high for HALO stock?
The 52-week high for Halozyme Therapeutics is $83.50. The current close of $81.48 is 2.4% below that high.
What is the 52-week low for HALO stock?
The 52-week low for Halozyme Therapeutics is $57.68. The current close of $81.48 is 41.3% above that low.
Does HALO stock pay dividends?
Halozyme Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for HALO?
Halozyme Therapeutics's Debt / Equity ratio is 9.77.